Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224149 | 0.78 | L3MBTL1 (0.44) | MEN1KMT2AL3MBTL1ALOX15 | |
| SCHEMBL12795929 | 0.72 | CA1 (0.33) | — | |
| SCHEMBL12848863 | 0.70 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL26710150 | 0.65 | NOTUM (0.31) | — | |
| SCHEMBL2408531 | 0.65 | POLB (0.32) | — | |
| SCHEMBL22789195 | 0.65 | — | — | |
| SCHEMBL20047620 | 0.65 | STS (0.37) | MEN1KMT2AL3MBTL1ALOX15 | |
| SCHEMBL2406497 | 0.64 | CYP2A6 (0.34) | — | |
| SCHEMBL2408528 | 0.64 | GABRA1 (0.38) | L3MBTL1 | |
| SCHEMBL14533257 | 0.64 | CYP2A6 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | MEN1 3623/4885KMT2A 3153/4885L3MBTL1 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.